Physician profile
Jonathan E Schwartz
NPI 1437101755
$4,576.07
in general payments reported to CMS, 2019-2025
41 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $412 · 2021: $339 · 2022: $319 · 2023: $939 · 2024: $1,448 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Long Term Medical Supply Or Device Loan: $598 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.97 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $707.69 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $424.20 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $329.21 | 2019-2024 | Keytruda |
| Amgen INC. | $237.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $220.86 | 2019-2023 | Opdivo |
| Pfizer INC. | $217.95 | 2019-2024 | |
| Astellas Pharma US INC | $187.31 | 2019-2024 | Xospata, Xtandi |
| Janssen Biotech, INC. | $176.58 | 2019-2024 | Rybrevant, Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $162.22 | 2019-2025 | |
| Genentech USA, INC. | $156.14 | 2019-2024 | Tecentriq, Alecensa, Rozlytrek |
| Regeneron Healthcare Solutions, INC. | $154.61 | 2022-2024 | Libtayo |
| Myovant Sciences INC. | $151.54 | 2021-2022 | |
| Incyte Corporation | $144.28 | 2022-2025 | Jakafi |
| Celgene Corporation | $136.61 | 2019-2024 | Reblozyl |
| Daiichi Sankyo INC. | $128.65 | 2023-2024 | Enhertu, Vanflyta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.